Hemangiosarcoma (HSA) is an aggressive disease that is fairly common in the dog. The authors evaluated a doxorubicin, dacarbazine, and vincristine (DAV) combination protocol in dogs with nonresectable stage II and stage III HSA. Twenty-four dogs were enrolled in this prospective, phase 2 study. Doxorubicin and dacarbazine were administered on day 1 while vincristine was administered on days 8 and 15. The protocol was repeated every 21 days for a maximum of six cycles or until disease progression. Toxicity and efficacy were assessed by clinical and laboratory evaluation and by questionnaires completed by the owners. Of the 24 included dogs, 19 were evaluable for response. The response rate (including five complete responses and four partial responses) was 47.4%. Median time to tumor progression was 101 days and median overall survival was 125 days.
Introduction
Hemangiosarcoma (HSA) is a malignant tumor that arises from endothelial cells. The disease is fairly common in the dog, representing approximately 5% of all canine noncutaneous primary malignancies. In contrast, HSA is extremely rare in humans where it represents less than 2% of all soft tissue sarcomas and only 100 cases of splenic HSA have been reported. [1] [2] [3] [4] German shepherd dogs, golden retrievers, Labrador retrievers, and schnauzers appear to be predisposed. 5, 6 Canine noncutaneous HSA is typically a highly malignant tumor, frequently metastasizing to distant organs such as the liver, lungs, heart, skin, and central nervous system. 7, 8 Many patients present with internal bleeding due to tumor rupture or disseminated intravascular coagulation. 2, [9] [10] [11] [12] Surgery may be palliative to arrest active hemorrhage, but does not provide long-term survival for the majority of cases with visceral involvement. 8, 11, 13, 14 Chemotherapy in the adjuvant setting has been evaluated in various clinical studies and has shown promise in prolonging life after surgical resection of the primary HSA lesion. [15] [16] [17] [18] [19] Most of those studies included dogs with different clinical stages of disease.
It appears that dogs with gross metastatic disease at the time of diagnosis (i.e., stage III) carried significantly worse prognoses, with reported median survival durations between 68 and 136 days. 17, 20, 21 The most effective chemotherapy protocols for the treatment of canine HSA are anthracycline-based. Doxorubicin and its analog epirubicin have been used: as single agents in the standard 3 wk protocol; in a dose-intense fashion (2 wk protocol); in combination with cyclophosphamide; or with cyclophosphamide and vincristine. [20] [21] [22] [23] [24] [25] [26] There have been no studies specifically evaluating the treatment of dogs with grossly metastatic HSA, a common presentation in the cases of HSA. 8, 10, 12 Nonresectable, primary, noncutaneous HSA appears to carry a negative prognosis for overall survival (OS), yet the use of chemotherapy or palliative radiation therapy has been largely unexplored. 27 This study evaluated the efficacy of a combination chemotherapy protocol comprised of doxorubicin, dacarbazine, and vincristine (DAV) for the treatment of advanced-stage canine noncutaneous HSA. Dogs were considered to have advanced-stage disease when a nonresectable, primary tumor and/or gross metastatic disease were present at the time of diagnosis. Dacarbazine (DTIC) is an alkylating agent used in the treatment of relapsed round cell tumors, high-grade sarcomas, and malignant melanomas. [28] [29] [30] [31] Results of both in vitro and in vivo studies suggest that DTIC acts synergistically with anthracyclines and has a moderate effect in the treatment of high-grade sarcomas in humans. [32] [33] [34] [35] [36] Vincristine has demonstrated modest responses in a limited number of canine HSA patients. 25, 37 The authors hypothesized that the DAV combination would be effective in providing clinical responses in dogs with advanced-stage noncutaneous HSA. 
Materials and Methods

Animals
Evaluation of Response and Toxicity
In all dogs, a complete blood count (CBC) and complete physical examination were performed on days 1, 7, 15, and 22 of treatment. by increased tumor size were also defined as progressive disease.
Toxicoses were identified on the basis of history and results of physical examinations and CBCs. Criteria established by the Veterinary Co-operative Oncology Group were used to grade toxicoses ( Table 1) .
43
Statistical Analysis
The study was structured with a two-stage design to allow early study closure if the overall clinical benefit rate was unacceptably low. 44, 45 In the first stage, 10 patients were entered. If two or more clinical responses were seen in the first stage of the study, then an additional 12 patients were entered into the study for a planned total of 22 cases. If seven or more clinical responses were observed in total, then the conclusion was that the chemotherapeutic protocol was effective. If less than seven responses were noted in the total patient sample population, then the conclusion was that there was insufficient anticancer activity of the DAV protocol to support continued evaluation. This study was designed for a Type 
Results
Patients
Twenty-four dogs were enrolled in the study, including 14 males.
Breeds represented in the study were: German shepherds (n¼7), Twenty-two dogs were euthanized due to HSA progression. Of the two dogs not euthanized due to PD, one dog was euthanized due to acute renal failure while in CR and the other dog was found dead by the owners 1 day after a complete restaging (i.e., CBC, serum chemistry, urinalysis, thoracic radiographs, abdominal 
Toxicity
The most common treatment-related toxicoses were hematologic and gastrointestinal. Overall, 221 hematologic toxic events were noted in the 24 dogs. Of these toxicities, 23 were grade 3 and 18
were grade 4. Grade 3 toxicities included anemia (n¼9), neutropenia (n¼12), and thrombocytopenia (n¼2). Grade 4 toxicities included anemia (n¼4), neutropenia (n¼10), and thrombocytopenia (n¼4). A total of 96 events of gastrointestinal toxicoses were observed. Of these events, eight were grade 3, and four were grade 4 toxicities. Grade 3 toxicities included anorexia (n¼1), emesis (n¼3), and diarrhea (n¼4). Grade 4 toxicities included emesis (n¼2) and diarrhea (n¼2).
The mean hematocrit of the treated dogs at the beginning of their therapy with the DAV protocol was 36.1% (6 5.16%). At the end of the treatment protocol, the mean hematocrit was 33.6% (6 7.8%; reference range, 40-55%). The mean platelet number at the beginning of the treatment with the DAV protocol was 382 3 10 3 /mL 6 237 3 10 3 /mL). At the end of the treatment protocol, the mean platelet number was 451 3 10 3 /mL 6 179 3 10 3 /mL (reference range, 155-393 3 10 3 /mL). These differences were not statistically significant. The toxicity of the DAV protocol appears to be significant. Five dogs were withdrawn from the study by their owners due to hematologic and/or gastrointestinal toxicities. All toxic events were observed after the administration of doxorubicin and DTIC. None of these five dogs received any type of additional chemotherapy after the toxic events. Further, the median OS of these five dogs was significantly shorter than the remaining patients included in the responses to treatment, TTPs, and OSs were not significantly different to dogs for which the diagnosis was based on histopathology. Therefore, these three dogs were included in the overall analysis.
Conclusion
The DAV protocol appears to be active against advanced-stage, 
